Category: Thoratec Corp.
Thoratec warns patients with its HeartMate II heart pump about the risk of switching controllers after receiving reports of 4 deaths.
Thoratec (NSDQ:THOR) said it sent out a warning about its HeartMate II left ventricular assist device after receiving reports of 4 deaths associated with switching out the heart pump's controller.
Company officials at Thoratec discuss the company's Q4 2013 earnings call. The company reported profits of $13.1 million, or 23¢ per diluted share, on sales of $128.2 million during the 3 months ended December 28, swinging to the black on a minor dip in sales.
Thoratec gains after posting a swing to the black for its 4th quarter, driven primarily by freedom from impairment charges, and projects strong growth in 2014.
California medical device maker Thoratec (NSDQ:THOR) posted another strong quarter to cap off a year of growth in sales and fewer hits to revenues.
A Thoratec shareholder seeks a class action lawsuit against the heart pump maker, accusing it of failing to warn investors about a blood clot problem with its flagship HeartMate II left ventricular assist device that allegedly contributed to a Class I recall.
In case you couldn't make it to sunny San Francisco, here are some of the best medical device stories that came out of the J.P. Morgan Healthcare conference this week.
HeartWare International's 4th-quarter preliminary sales numbers miss the mark on Wall Street, prompting investors to send its share price down.
HeartWare International (NSDQ:HTWR) said it expects to report 4th-quarter revenues of roughly $53 million, missing the consensus view on Wall Street of $58 million and sending its share price down sharply in pre-market trading.
Thoratec president & CEO Gary Burbach says that survival and adverse event rates associated with the company's HeartMate II LVAD have improved significantly compared to what was reported in a New England Journal of Medicine article late last year.